Bridgefront Capital’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-17,765
Closed -$1.43M 508
2025
Q4
$1.43M Buy
17,765
+7,870
+80% +$659K 0.36% 74
2025
Q3
$966K Buy
+9,895
New +$797K 0.28% 95
2025
Q2
Sell
-5,174
Closed -$257K 581
2025
Q1
$257K Buy
+5,174
New +$327K 0.07% 439
2024
Q4
Sell
-2,464
Closed -$258K 555
2024
Q3
$258K Buy
+2,464
New +$288K 0.1% 379
2024
Q2
Sell
-3,109
Closed -$347K 471
2024
Q1
$347K Buy
+3,109
New +$370K 0.26% 145
2021
Q1
Sell
-11,454
Closed -$334K 643
2020
Q4
$334K Buy
+11,454
New +$296K 0.11% 335

Other funds holding ACLS

Bridgefront Capital's ACLS Position: Q1 2026 in Review

Bridgefront Capital sold out of Axcelis (ACLS) in Q1 2026, closing a stake of 17,765 shares — an estimated $1.43M sold.

Bridgefront Capital first reported a position in ACLS in Q4 2020 and held it in 6 quarters. The position peaked at $1.43M in Q4 2025. 377 funds tracked by Wall St. Rank hold ACLS as of Q1 2026.

  • Bridgefront Capital reported no remaining Axcelis position as of Q1 2026 after selling out during the quarter.
  • Bridgefront Capital sold 17,765 Axcelis shares in Q1 2026, an estimated $1.43M.
  • Bridgefront Capital first reported a position in Axcelis in Q4 2020 and held it in 6 quarters.
  • Bridgefront Capital's Axcelis position peaked at $1.43M in Q4 2025.
  • 377 funds tracked by Wall St. Rank held Axcelis as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.